Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial

Clinical Infectious Diseases

Volumn 59, Issue 7, 2014, Pages 1020-1026

  Solomon, Marc M ^a,b   Mayer, Kenneth H ^d,e   Glidden, David V ^b   Liu, Albert Y ^c   McMahan, Vanessa M ^a   Guanira, Juan V ^f   Chariyalertsak, Suwat ^g   Fernandez, Telmo ^h   Grant, Robert M ^a,b   Bekker, Linda Gail ⁱ   Buchbinder, Susan ⁱ   Casapia, Martin ⁱ   Kallas, Esper ⁱ   Lama, Javier ⁱ   Montoya, Orlando ⁱ   Schechter, Mauro ⁱ   Veloso, Valdiléa ⁱ  

^a GLADSTONE INSTITUTES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d FENWAY INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Investigaciones Medicas en Salud   (Peru)

^g Faculty of Medicine Chiang Mai University   (Thailand)

^h Fundacion Ecuatoriana Equidad   (Ecuador)

ⁱ NONE

Author keywords

Chemoprophylaxis; HIV prevention; MSM; Preexposure prophylaxis; Syphilis

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MALE TO FEMALE TRANSGENDER; MEN WHO HAVE SEX WITH MEN; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAGIN TEST; SCREENING TEST; SYPHILIS; YOUNG ADULT; ANALOGS AND DERIVATIVES; COMPLICATION; FEMALE; HIV INFECTIONS; INCIDENCE; MALE HOMOSEXUALITY; MIDDLE AGED; PREVALENCE; PROCEDURES; TRANSGENDER; TRANSMISSION; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-HIV AGENTS; DEOXYCYTIDINE; EMTRICITABINE; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PLACEBOS; PRE-EXPOSURE PROPHYLAXIS; PREVALENCE; SYPHILIS; TENOFOVIR; TRANSGENDER PERSONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964314488     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu450     Document Type: Article

References (39)

1. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. Geneva, Switzerland: WHO, 2012.
2. Sexton J, Garnett G, Rottingen JA. Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005; 32:351-7.
3. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
4. Dickerson MC, Johnston J, Delea TE, White A, Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria. Sex Transm Dis 1996; 23:429-40.
5. Clottey C, Dallabetta G. Sexually transmitted diseases and human immunodeficiency virus. Epidemiologic synergy? Infect Dis Clin North Am 1993; 7:753-70.
6. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
7. Mertens TE, Hayes RJ, Smith PG. Epidemiological methods to study the interaction between HIV infection and other sexually transmitted diseases. AIDS 1990; 4:57-65.
8. Cameron DW, Padian NS. Sexual transmission of HIV and the epidemiology of other sexually transmitted diseases. AIDS 1990;4(suppl 1): S99-103.
9. Fox J, Fidler S. Sexual transmission of HIV-1. Antiviral Res 2010; 85:276-85.
10. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:305-10.
11. Jarzebowski W, Caumes E, Dupin N, et al. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med 2012; 172:1237-43.
12. Buchacz K, Klausner JD, Kerndt PR, et al. HIV incidence among men diagnosed with early syphilis in Atlanta, San Francisco, and Los Angeles, 2004 to 2005. J Acquir Immune Defic Syndr 2008; 47:234-40.
13. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
14. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
15. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
16. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2013; 381:2083-90.
17. Duwal S, Schutte C, von Kleist M. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One 2012; 7:e40382.
18. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra25.
19. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. Atlanta, GA: CDC, 2006.
20. Aynalem G, Smith L, Bemis C, Taylor M, Hawkins K, Kerndt P. Commercial sex venues: a closer look at their impact on the syphilis and HIV epidemics among men who have sex with men. Sex Transm Infect 2006; 82:439-43.
21. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 2010; 53:537-43.
22. Feng Y, Wu Z, Detels R, et al. HIV/STD prevalence among men who have sex with men in Chengdu, China and associated risk factors for HIV infection. J Acquir Immune Defic Syndr 2010; 53(suppl 1): S74-80.
23. Hope-Rapp E, Anyfantakis V, Fouere S, et al. Etiology of genital ulcer disease. A prospective study of 278 cases seen in an STD clinic in Paris. Sex Transm Dis 2010; 37:153-8.
24. Huhn GD, McIntyre AF, Broad JM, et al. Factors associated with newly diagnosed HIV among persons with concomitant sexually transmitted diseases. Sex Transm Dis 2008; 35:731-7.
25. Katz KA, Lee MA, Gray T, Marcus JL, Pierce EF. Repeat syphilis among men who have sex with men - San Diego County, 2004-2009. Sex Transm Dis 2011; 38:349-52.
26. Scott KC, Philip S, Ahrens K, Kent CK, Klausner JD. High prevalence of gonococcal and chlamydial infection in men who have sex with men with newly diagnosed HIV infection: an opportunity for same-day presumptive treatment. J Acquir Immune Defic Syndr 2008; 48:109-12.
27. Torrone EA, Bertolli J, Li J, et al. Increased HIV and primary and secondary syphilis diagnoses among young men - United States, 2004-2008. J Acquir Immune Defic Syndr 2011; 58:328-35.
28. Wilkinson D, Rutherford G. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev 2001:CD001220.
29. World Health Organization. Data on other STIs: men who have sex with men (MSM) with active syphilis by country. Available at: http://apps. who.int/gho/data/node.main.A1361STI. Accessed 14 April 2014.
30. Centers for Disease Control and Prevention. STDs in men who have sex with men. Available at: http://www.cdc.gov/std/stats11/msm.htm. Accessed 14 April 2014.
31. Pinkerton SD. Sexual risk compensation and HIV/STD transmission: empirical evidence and theoretical considerations. Risk Anal 2001; 21:727-36.
32. CassellMM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006; 332:605-7.
33. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994; 265:1451-4.
34. Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One 2013; 8:e81997.
35. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
36. Gilead Sciences. Highlights of prescribing information. Available at: http://www.gilead.com/approximately/media/Files/pdfs/medicines/hiv/ truvada/truvada-pi.PDF. Accessed 14 April 2014.
37. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep 2012; 61:586-9.
38. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65-8.
39. Buchbinder SP, Glidden DV, Liu AY, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis 2014; 14:468-75.